These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1546 related articles for article (PubMed ID: 33212256)

  • 21. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
    Udwadia ZF; Barkate H; Patil S; Rangwala S; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Apr; 105():686-687. PubMed ID: 33601032
    [No Abstract]   [Full Text] [Related]  

  • 22. Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
    Sirijatuphat R; Manosuthi W; Niyomnaitham S; Owen A; Copeland KK; Charoenpong L; Rattanasompattikul M; Mahasirimongkol S; Wichukchinda N; Chokephaibulkit K
    Emerg Microbes Infect; 2022 Dec; 11(1):2197-2206. PubMed ID: 35997325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.
    Suemori K; Saijo M; Yamanaka A; Himeji D; Kawamura M; Haku T; Hidaka M; Kamikokuryo C; Kakihana Y; Azuma T; Takenaka K; Takahashi T; Furumoto A; Ishimaru T; Ishida M; Kaneko M; Kadowaki N; Ikeda K; Sakabe S; Taniguchi T; Ohge H; Kurosu T; Yoshikawa T; Shimojima M; Yasukawa M
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009103. PubMed ID: 33617533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.
    Shah PL; Orton CM; Grinsztejn B; Donaldson GC; Crabtree Ramírez B; Tonkin J; Santos BR; Cardoso SW; Ritchie AI; Conway F; Riberio MPD; Wiseman DJ; Tana A; Vijayakumar B; Caneja C; Leaper C; Mann B; Samson A; Bhavsar PK; Boffito M; Johnson MR; Pozniak A; Pelly M;
    Lancet Respir Med; 2023 May; 11(5):415-424. PubMed ID: 36528039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV).
    Siripongboonsitti T; Tawinprai K; Avirutnan P; Jitobaom K; Auewarakul P
    J Infect Public Health; 2024 May; 17(5):897-905. PubMed ID: 38569269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
    Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.
    Bosaeed M; Alharbi A; Hussein M; Abalkhail M; Sultana K; Musattat A; Alqahtani H; Alshamrani M; Mahmoud E; Alothman A; Alsaedy A; Aldibasi O; Alhagan K; Asiri AM; AlJohani S; Al-Jeraisy M; Alaskar A
    BMJ Open; 2021 Apr; 11(4):e047495. PubMed ID: 33853806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
    Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
    J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
    Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
    Ömeroğlu ŞK; Temel F; Altun D; Öztop B
    Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.
    AlQahtani M; Kumar N; Aljawder D; Abdulrahman A; Mohamed MW; Alnashaba F; Fayyad MA; Alshaikh F; Alsahaf F; Saeed S; Almahroos A; Abdulrahim Z; Otoom S; Atkin SL
    Sci Rep; 2022 Mar; 12(1):4925. PubMed ID: 35322077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Favipiravir-induced Fever in a Patient with COVID-19.
    Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R
    Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 78.